WO2024224359 - METHOD FOR EXPANDING CD56+/CD3- CELLS
National phase entry:
Publication Number
WO/2024/224359
Publication Date
31.10.2024
International Application No.
PCT/IB2024/054093
International Filing Date
26.04.2024
Title **
[English]
METHOD FOR EXPANDING CD56+/CD3- CELLS
[French]
PROCÉDÉ D'EXPANSION DE CELLULES CD56+/CD3-
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
KASSAI, Yoshiaki
SEKIYA, Keiko
SHI, Xi
Priority Data
63/498,773
27.04.2023
US
63/572,039
29.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2968 | |
| EPO | Filing, Examination, Granting | 19731 | |
| Japan | Filing, Examination, Granting | 2794 | |
| South Korea | Filing, Examination, Granting | 3292 | |
| USA | Filing, Examination, Granting | 10140 |
Total:
38,925
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
cells with an NKp46 agonist and/or a CD30 agonist.[French]
La présente invention concerne des procédés d'expansion ou de production de cellules CD56+/CD3- comprenant la mise en contact des cellules CD56+/CD3- avec un agoniste de NKp46 et/ou un agoniste de CD30.